Biomimetic Therapeutics, LLC

Biomimetic Therapeutics, LLC specializes in synthetic bone matrix implants, which are primarily used in orthopedic and maxillofacial surgeries. These devices come in both injectable and granular forms, designed to support bone regeneration and structural repair during grafting procedures. The focus is on non-antimicrobial synthetic materials, ensuring compatibility with bone-healing processes.

Biomimetic Therapeutics, LLC is based in the United States. Since the company’s devices fall under FDA Class III classification, they are subject to stringent regulatory oversight, including Premarket Approval (PMA) requirements. This classification applies to devices that support or sustain life, are of substantial importance in preventing impairment, or present a potential unreasonable risk of illness or injury. The U.S. location means compliance with FDA regulations is mandatory for device authorization.

Biomimetic Therapeutics, LLC’s devices are listed under the FDA’s Premarket Approval (PMA) program, which is required for high-risk Class III devices. Additionally, the company’s products are included in the FDA’s Unique Device Identifier (UDI) system, a standardized system for tracking medical devices throughout their lifecycle. These registries ensure traceability and compliance with U.S. regulatory requirements.

Biomimetic Therapeutics, LLC’s devices are classified as FDA Class III. This classification is reserved for devices that pose a high risk to patients and require rigorous pre-market approval to ensure safety and effectiveness. Since bone matrix implants can directly impact critical functions like structural integrity and bone regeneration, they fall under this stringent category to mitigate potential risks such as infection, improper integration, or failure of the implant.